Renal Cell Carcinoma Metastatic Clinical Trial
Official title:
Targeting PIM1 and CDK4/6 Kinases in Renal Cell Carcinoma (PICKRCC): A Phase Ib Study of Abemaciclib (VerzenioTM) in Combination With Sunitinib in Metastatic Renal Cell Carcinoma
The purpose of this study is to determine the safety, tolerability, and maximal tolerated dose (MTD) of the combination of Abemaciclib and Sunitinib administered orally in patients with advanced and metastatic renal cell carcinoma. This study consists of two parts: Dose Escalation and Dose Expansion. During the dose escalation phase, participants will be sequentially enrolled in a standard 3 x 3 dose escalation study design to receive oral Abemaciclib in Combination with Sunitinib. The purpose of this dose escalation is to determine the maximal tolerated dose based on assessment of any dose limiting toxicity. The Dose Expansion Phase will enroll additional participants at the established maximal tolerated dose to further evaluate safety, tolerability, as well as the pharmacokinetics and pharmacodynamics of this combination drug regimen.
Renal cell carcinoma (RCC) accounted for about 64, 000 new cancer diagnoses in the USA in 2018. Up to 30% of those diagnoses will be patients with metastatic disease. Additionally, up to 50% of patients who undergo partial or radical nephrectomy will develop metastatic disease.. There is no cure for metastatic RCC, thus, metastatic RCC represents a significant cancer burden. Numerous directed therapies are available to improve overall survival but these do not result in durable complete responses. However, recent pre-clinical studies of RCC have demonstrated that Abemaciclib, a CDK4/6 and PIM1 kinase inhibitor, induces rapid, dramatic, and sustained tumor regression when used in combination with Sunitinib. Our objectives for this study are as follows: Primary Objectives: - Determine the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) of the combination of Abemaciclib with Sunitinib for patients with metastatic renal cell carcinoma. Additionally, determine pharmacokinetics (serum trough levels) of Abemaciclib and Sunitinib at steady state. - Continued safety assessment of the combination of Abemaciclib and Sunitinib at the established maximum tolerated dose (i.e. the recommended Phase II dose) Secondary Objectives: Determine any anti-tumor activity in the dose expansion phase of the study. Tumor related activity will be assessed by: - Length of progression free survival - Disease response rate - Time to disease response - Disease control rate - Duration of response - Overall survival and progression free survival ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05548621 -
A Prospective Study to Evaluate the Implementation of Shared Decision Making Strategy for Renal Cell Cancer (RCC)
|
||
| Recruiting |
NCT04659343 -
TDM for Optimized Outcome in Patients With mRCC.
|
||
| Terminated |
NCT06377722 -
Cabozantinib Treatment Prior to Cytoreductive Nephrectomy in Patients With Advanced or Metastatic Renal Cells Cancer
|
Phase 2 | |
| Completed |
NCT06161233 -
Pilot Study of the eHealth Application "Cancer Patients Better Life Experience" (CAPABLE) - Italy
|
N/A | |
| Not yet recruiting |
NCT06321250 -
A Study of JMKX003948 Tablets in Patients With Renal Cell Carcinoma
|
Phase 1 | |
| Recruiting |
NCT04764487 -
A Web-mediated Follow-up With the Web-application KidneyPRO Versus Standard Follow-up for Patients With Advanced Renal Cell Carcinoma Treated With Axitinib/Pembrolizumab in First Line
|
Phase 3 | |
| Recruiting |
NCT03977571 -
Deferred Cytoreductive Nephrectomy in Synchronous Metastatic Renal Cell Carcinoma: The NORDIC-SUN-Trial
|
N/A | |
| Completed |
NCT03699579 -
Pharmaco-Economic Study of Treatment Options in Patients With Advanced RCC
|
||
| Terminated |
NCT05103722 -
Combined Aerobic and Resistance Exercise Training in Metastatic Renal Cell Carcinoma
|
N/A |